COMPANY

AyuVis Research, Inc.

HQ: Fort Worth, TX source · ayuvis.com ↗ · Southwest

Clinical Phase 1

Also known as AyuVis Research · 10 sources

Keywords: small molecule bronchopulmonary dysplasia lung disease sepsis Safety Issues Pharmacodynamics AVR-48

Location: Fort Worth, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)7NIH grants

Funding and NIH signals

NIH award NIH awarded $360K (SBIR Phase II 5R44HD112276-03, continuation, notice May 25, 2026). NIH RePORTER 5R44HD112276-03 (May 25, 2026)
Evidence (1 event)
- May 25, 2026 · NIH RePORTER 5R44HD112276-03
  Organization: AYUVIS RESEARCH, INC.; City/State: FORT WORTH, TX; Project number: 5R44HD112276-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 359812; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

May 25, 2026 Grant Government grant — SBIR: $359,812 (annual award, as published), announced May 25, 2026. Agency: NIH/NICHD. Source: government award database. source ↗
2025-06 Trial start Phase 1: Single Ascending Dose and Multiple Ascending Dose Study of AVR-48 source ↗
Mar 27, 2025 Grant Government grant — SBIR: $712,481 (annual award, as published), announced Mar 27, 2025. Agency: NIH/NICHD. Source: government award database. source ↗

Funding

Last 2 years.

May 25, 2026 Government grant — SBIR: $359,812 (annual award, as published), announced May 25, 2026. Agency: NIH/NICHD. Source: government award database. source ↗
Mar 27, 2025 Government grant — SBIR: $712,481 (annual award, as published), announced Mar 27, 2025. Agency: NIH/NICHD. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06847698	Single Ascending Dose and Multiple Ascending Dose Study of AVR-48	Phase 1	Not yet recruiting	2025-06	2025-10 (estimated)

NIH awards 7

Annual award amounts. Total $3.7M.

Apr 29, 2024 NIH award 5R61HL164372-02 FY2024: $279,788 awarded for that fiscal year; activity R61 (OTHER_NIH); PI ACHARYA, SUCHISMITA; recipient as written: AYUVIS RESEARCH, INC., FORT WORTH, TX. Phase-1 Healthy adult human safe source ↗
Apr 12, 2024 NIH award 1R44HD112276-01A1 FY2024: $895,365 awarded for that fiscal year; activity R44 (SBIR); PI ACHARYA, SUCHISMITA; recipient as written: AYUVIS RESEARCH, INC., FORT WORTH, TX. Phase 1 Safety, Pharmacokinetic stu source ↗
May 25, 2023 NIH award 3R44HD107857-02S1 FY2023: $203,967 awarded for that fiscal year; activity R44 (SBIR); PI ACHARYA, SUCHISMITA; recipient as written: AYUVIS RESEARCH, INC., FORT WORTH, TX. A novel approach for prevention of source ↗
Apr 30, 2023 NIH award 1R61HL164372-01A1 FY2023: $270,788 awarded for that fiscal year; activity R61 (OTHER_NIH); PI ACHARYA, SUCHISMITA; recipient as written: AYUVIS RESEARCH, INC., FORT WORTH, TX. Phase-1 Healthy adult human sa source ↗
Mar 28, 2023 NIH award 5R44HD107857-02 FY2023: $702,096 awarded for that fiscal year; activity R44 (SBIR); PI ACHARYA, SUCHISMITA; recipient as written: AYUVIS RESEARCH, INC., FORT WORTH, TX. A novel approach for prevention of Br source ↗
May 1, 2022 NIH award 1R44HD107857-01A1 FY2022: $1,109,134 awarded for that fiscal year; activity R44 (SBIR); PI ACHARYA, SUCHISMITA; recipient as written: AYUVIS RESEARCH, INC., FORT WORTH, TX. A novel approach for prevention o source ↗
Jan 9, 2017 NIH award 1R43AI129164-01 FY2017: $273,826 awarded for that fiscal year; activity R43 (SBIR); PI ACHARYA, SUCHISMITA; recipient as written: AYUVIS RESEARCH, INC., FORT WORTH, TX. Novel multifunctional oligosaccharide source ↗